The liver test that could spare a biopsy—but only for the question it answers well

Source: The Lancet, issue dated October 31, 2026; LITMUS prospective multicenter diagnostic-accuracy study, DOI 10.1016/S0140-6736(26)01145-1, PubMed. Evidence: substantial prospective diagnostic comparison, not an outcome trial. Clinical state: promising for diagnostic-pathway design; assay selection/indication require validation.

Metabolic liver disease often progresses silently until its consequences are serious. Now that treatments are advancing, the immediate obstacle is identifying the right people without sending everyone for an invasive biopsy. The LITMUS investigators enrolled 1,590 adults with biopsy-confirmed disease across 13 countries, centrally reviewed the histology, and compared a dozen individual biomarkers with 18 panels.

The most discriminating assay depended on what clinicians were trying to diagnose. For advanced fibrosis, SomaSignal reached an area under the receiver-operating curve (AUC 0.92, 95% CI 0.90–0.94); FibroMeter combined with vibration-controlled elastography reached 0.87. For at-risk steatohepatitis—inflammation plus fibrosis stage 2 or higher—SomaSignal reached 0.83 (0.80–0.85). For cirrhosis, FibroMeter-VCTE reached 0.94. Those are promising ranking measures, not the chance that a particular positive test is correct; predictive values depend on prevalence, selected thresholds and the next decision.

What this changes: We may be approaching more effective tiered pathways: cheap initial tests, focused multiparameter tests, biopsy when uncertainty still matters. But the biopsy-enriched cohort and comparison conditions can differ from an ordinary community screening population, and no test's AUC by itself proves fewer cirrhosis complications or better survival.